skip links

Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
March 30, 2010

Ironwood Pharmaceuticals Files Annual Report on Form 10-K

February 16, 2010

Underwriters Exercise Over-Allotment Option for Ironwood Pharmaceuticals’ Initial Public Offering

November 20, 2009

Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering

November 10, 2009

Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide

November 2, 2009

Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials In Patients with Chronic Constipation

October 27, 2009

Marsha Fanucci Joins Ironwood Board of Directors

September 14, 2009

David Ebersman Joins Ironwood Board of Directors

September 14, 2009

Ironwood Appoints Thomas McCourt as Chief Commercial Officer and Senior Vice President of Marketing and Sales

May 31, 2009

Ironwood And Forest Present Additional Positive Phase 2b Study Results For Linaclotide In Patients With Irritable Bowel Syndrome With Constipation

May 12, 2009

Ironwood And Forest To Present Additional Phase 2b Data For Novel Gastrointestinal Agent Linaclotide

May 4, 2009

Ironwood Announces Linaclotide European Licensing Agreement With Almirall

October 21, 2008

Ironwood Presents Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

October 7, 2008

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

October 6, 2008

Ironwood and Collaborators Present Preclinical Data Demonstrating that Cyclic GMP Alleviates Intestinal Pain

October 1, 2008

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3